Every 8-K that ALX Oncology Holdings Inc. (ALXO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ALXO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALXO filings page.
ALX Oncology Holdings Inc. reported second quarter 2026 results, with GAAP net loss of $18.0 million for the three months ended June 30, 2026, compared with $25.9 million a year earlier. Cash, cash equivalents and investments were $153.4 million as of June 30, 2026, which the company expects will fund planned operations through the first half of 2028.
Research and development expenses were $13.1 million, down from $18.0 million, reflecting lower legacy trial costs while continuing to invest in the Phase 2 ASPEN-09-Breast evorpacept trial and the Phase 1 ALX2004 study. Non-GAAP net loss was $14.3 million, compared with $20.6 million in the prior-year quarter.
The company highlighted progress in its oncology pipeline, including biomarker-driven evorpacept data presented at ESMO Breast Cancer 2026 and ongoing enrollment in ASPEN-09-Breast with topline data from 80 patients expected in mid-2027. Enrollment continues in the Phase 1 ALX2004 antibody-drug conjugate trial in EGFR-expressing solid tumors, with initial safety data expected in the second half of 2026. ALX Oncology refinanced $10 million of existing debt and entered into a secured multi-tranche term loan facility of up to $50 million, including the ability to draw an additional $20 million through June 2028, and appointed Scott Garland as Chairman and Michael Listgarten as General Counsel.
ALX Oncology Holdings Inc. reported a planned leadership transition at the board level. Corey Goodman, Ph.D., co-founder and long-time Chairman, resigned from the board and all its committees effective June 29, 2026, citing personal reasons and no disagreements with the company.
The board appointed existing independent director Scott Garland as Chairman effective the same date and named Michael Listgarten as General Counsel. Committee memberships were updated, with Rekha Hemrajani chairing Audit, Chris Takimoto chairing Compensation, and Daniel J. Curran chairing Corporate Governance and Nominating, reflecting a refreshed governance structure.
ALX Oncology Holdings Inc. entered into a new secured multi-tranche term loan facility of up to $50,000,000 with HSBC Ventures USA Inc. on June 25, 2026. The company drew $10,000,000 at closing to refinance its prior Oxford Finance and Silicon Valley Bank loan and pay fees, with remaining proceeds available for general corporate purposes.
An additional $20,000,000 is available to draw through June 30, 2028, with a further $10,000,000 tied to achieving positive data milestones in the Phase 2 ASPEN-09 study of Evorpacept and positive safety data in the Phase 1 study of ALX2004. A final $10,000,000 may be provided at the lender’s sole discretion.
The loans mature on June 1, 2030 and bear a floating interest rate equal to the greater of the Prime Rate or 6.0%, with amortization beginning July 1, 2028 or, if an Interest Only Milestone Event occurs, July 1, 2029. The facility is secured by substantially all assets (with a negative pledge on intellectual property) and includes customary covenants and events of default that could accelerate repayment if breached.
ALX Oncology Holdings Inc. held its Annual Meeting of stockholders on June 10, 2026. Stockholders elected Class II directors Daniel Curran, M.D., Rekha Hemrajani, and Chris Takimoto, M.D., Ph.D., F.A.C.P. to serve until the 2029 annual meeting, each continuing until a successor is elected and qualified.
Stockholders also approved, on an advisory basis, the compensation of the company’s named executive officers, as described in the proxy statement. In addition, they ratified the appointment of KPMG LLP as ALX Oncology’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
ALX Oncology Holdings Inc. reported first quarter 2026 results showing a significantly narrower loss while advancing its cancer pipeline. GAAP net loss was $17.9 million, or $0.17 per share, compared with $30.8 million, or $0.58 per share, a year earlier. Non-GAAP net loss improved to $15.4 million from $25.5 million.
Research and development expenses fell to $13.6 million from $23.9 million, and general and administrative costs declined to $5.4 million from $7.9 million, mainly due to prior workforce reductions and pipeline prioritization. Cash, cash equivalents and investments totaled $169.1 million as of March 31, 2026, and the company expects this to fund operations through the first half of 2028.
Clinically, exploratory Phase 1b/2 data for CD47-inhibitor evorpacept plus zanidatamab in heavily pre-treated HER2-positive metastatic breast cancer showed a confirmed objective response rate of 60% and median progression-free survival of 8.3 months in centrally confirmed HER2-positive patients. All patients with HER2-positive disease and high CD47 expression responded, with a median duration of response of 20.2 months. The Phase 2 ASPEN-09-Breast trial remains on track for topline data in mid-2027, and the Phase 1 trial of EGFR-targeted ADC ALX2004 continues toward safety data in the second half of 2026.
ALX Oncology Holdings Inc. appointed Jeff Knight as Chief Development and Operating Officer, effective April 13, 2026. Knight is a veteran biopharmaceutical executive with more than three decades of experience in clinical development, regulatory affairs, and operational leadership at companies including Crinetics, Poseida, Halozyme, Amgen, Onyx, and Genentech.
Under his employment offer letter, Knight will receive an annual base salary of $565,000 and be eligible for an annual target cash bonus equal to 40% of base salary. He will also receive a stock option to purchase 800,000 shares of ALX Oncology common stock under the 2025 Inducement Equity Incentive Plan, vesting 25% after one year and the remainder in equal monthly installments over the following three years, subject to continued service.
He has entered into the company’s standard change of control and severance and indemnification agreements. A related press release highlighting his role in supporting upcoming clinical milestones for evorpacept and ALX2004 was furnished as an exhibit.
ALX Oncology reported 2025 results showing lower expenses and a stronger balance sheet while advancing two key cancer programs. Research and development spending fell to $77.0M from $116.4M, and general and administrative costs declined to $23.9M from $26.1M.
GAAP net loss narrowed to $101.7M, or $1.90 per share, from $134.9M, or $2.58 per share. The company ended 2025 with $48.3M in cash, cash equivalents and investments, then raised $150M in a registered equity offering, yielding $140.4M in net proceeds.
Management expects this cash to fund operations through the first half of 2028, covering major milestones for lead CD47 inhibitor evorpacept and EGFR-targeted ADC ALX2004. Multiple clinical data readouts are planned between 2026 and mid-2027, including biomarker analyses and Phase 1 safety results.
ALX Oncology Holdings Inc. entered an underwriting agreement to sell 76,979,112 shares of common stock and pre-funded warrants to purchase 18,574,120 shares, raising approximately $150 million in gross proceeds. The common stock is priced at $1.57 per share and the pre-funded warrants at $1.569 each.
The offering is fully underwritten by Piper Sandler, UBS and Wells Fargo and is expected to close on February 2, 2026, subject to customary conditions. Each pre-funded warrant has a $0.001 exercise price, can be exercised for cash or on a cashless basis, and includes ownership caps at 4.99% or 9.99%, adjustable up to 19.99% with advance notice.
ALX Oncology Holdings Inc. reported new early-stage clinical data and a preliminary year-end cash figure. The company highlighted topline findings from a Phase 1b/2 trial of its investigational CD47 inhibitor evorpacept combined with Jazz Pharmaceuticals’ ZIIHERA (zanidatamab-hrii) in heavily pretreated metastatic breast cancer patients.
In an exploratory analysis of HER2-positive metastatic breast cancer, CD47 expression appeared predictive of evorpacept activity. Separately, ALX Oncology estimated it held approximately $48.3 million in cash, cash equivalents, and short- and long-term investments as of December 31, 2025, noting this figure is unaudited, preliminary, and subject to change after completion of year-end closing procedures.
ALX Oncology Holdings Inc. updated its employee compensation plans by amending its 2025 Inducement Equity Incentive Plan. Effective January 21, 2026, the board of directors reserved an additional 1,300,000 shares of common stock for issuance under this plan, bringing the total shares reserved to 2,800,000. This plan is used to grant stock options, restricted stock, restricted stock units, stock appreciation rights and performance-based awards, primarily to new hires as a material inducement to join the company. The amendment and the original plan were approved by the board without stockholder approval, consistent with Nasdaq listing rules that allow inducement awards for individuals who were not previously employees or non-employee directors, or who are rehired after a bona fide break in service.
ALX Oncology Holdings Inc. reported that it issued a press release announcing its financial results for the third quarter and full year ended September 30, 2025. The press release is furnished as Exhibit 99.1.
The company furnished this information under Item 2.02. The materials, including Exhibit 99.1, are not deemed “filed” and are not subject to Section 18 liability, nor incorporated by reference unless expressly stated.
ALX Oncology disclosed that it furnished a press release reporting financial results for the second quarter and full year ended June 30, 2025. The filing itself does not include the financial detail but references Exhibit 99.1 for the full release.
The company also expanded its board from six to seven members by appointing Daniel Curran, M.D. as a Class III director. Dr. Curran brings over 25 years of pharmaceutical experience, including recent roles as CEO of Timberlyne Therapeutics and prior senior leadership at Takeda. He will join the Corporate Governance and Nominating Committee and is designated as independent under applicable Nasdaq and SEC standards.
Under the outside director compensation policy Dr. Curran will receive an initial option award to purchase 40,400 shares that vests monthly over 36 months and will be eligible for annual cash and equity awards; an indemnification agreement was also executed. The filing lists updated board committee memberships.